

AMENDMENTS TO THE CLAIMS

1. (Canceled)

2. (Currently amended) ~~A~~An isolated tumor antigen peptide that is a partial peptide of a protein consisting of the amino acid sequence of SEQ ID NO: 2, wherein the peptide comprises an amino acid sequence of any one of SEQ ID NOS: 3 to 52 and ~~that~~ binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.

3. (Original) The tumor antigen peptide of claim 2 wherein the HLA antigen is HLA-A24 or HLA-A2.

4. (Canceled)

5. (Currently amended) The tumor antigen peptide of ~~claim 4~~ claim 3 which comprises an amino acid sequence shown in any one of SEQ ID NOS: 3-9 and 25-29.

6. (Currently amended) A derivative of the tumor antigen peptide of ~~claim 4~~ claim 2, in which ~~the amino acid residue at position 2 and/or the C-terminus in the amino acid sequence shown in any one of SEQ ID NOS: 3-52 is substituted by another amino acid residue~~the amino acid residue at position 2 in the amino acid sequence shown in any one of SEQ ID NOS: 3-24 is substituted by tyrosine, phenylalanine, methionine, or tryptophan, and/or the amino acid residue at the C-terminus is substituted by phenylalanine, leucine, isoleucine, tryptophan, or methionine, and in which the derivative ~~that~~ binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.

7. (Currently amended) A derivative of the tumor antigen peptide of claim 5, ~~in which the amino acid residue at position 2 and/or the C-terminus in the amino acid sequence shown in any one of SEQ ID NOS: 3-9 and 25-29 is substituted by another amino acid residue, and in which the derivative~~ that comprises an amino acid sequence of any one of SEQ ID NOS: 53-64 and that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.

8. (Canceled)

9. (Withdrawn, currently amended) ~~The derivative of claim 6~~ A derivative of the tumor antigen peptide of claim 2, in which the amino acid residue at position 2 in the amino acid sequence shown in any one of SEQ ID NOS: 25-52 is substituted by leucine, methionine, valine, isoleucine, or glutamine, and/or the amino acid residue at the C-terminus is substituted by valine or leucine, that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.

10. (Canceled)

11. (Currently amended) A pharmaceutical composition for treating tumors, which comprises as an active ingredient at least one of substances selected from the tumor antigen peptides and the derivatives according to any one of ~~claims 2 to 10~~ 2, 5-7 and 9, and a pharmaceutically acceptable carrier.

12. (Currently amended) A recombinant polypeptide ~~obtainable-produced~~ by expressing the a recombinant DNA comprising at least one of ~~DNA's~~ polynucleotide that encodes the tumor antigen ~~peptides or the derivatives~~ peptide or derivative according to any one of claims ~~2, 3, 5-7 and 9 to 10.~~ 2, 3, 5-7 and 9.

13. (Currently amended) A pharmaceutical composition for treating ~~tumors~~ a tumor, which comprises as an active ingredient the recombinant polypeptide of claim 12, in an amount effective for treating said tumor and a pharmaceutically acceptable carrier.
14. (Currently amended) A diagnostic agent for tumors, which comprises the tumor antigen peptide or the derivative according to any one of claims 2, 3, 5-7 and 9 to 10.
15. (Original) A diagnostic agent for tumors, which comprises the recombinant polypeptide of claim 12.